Skip to content
DataLookout
Menu

NCT07066267

Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words
    • Enrollment closed, study ongoing
    • Site details revised
    • Publications: details revised at 3 of 3 entries
  2. Minor Publications: details revised at 3 of 3 entriesv2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Embryo development rate
Timeframe: Up to 8 weeks post-intervention

Secondary (6)

Ongoing clinical pregnancy rate after the first transfer
Chemical pregnancy rate
Live Birth rates
Pregnancy complication
Abortion rate
Show 1 moreShow less
Additional in vitro fertilization - outcome indicators

Arms and interventions

Autologous Mitochondria transferActive comparator

Mitochondria isolated from autologous adipose-derived stem cells are transplanted into the oocyte in conjunction with intracytoplasmic sperm injection (ICSI); Mito-ICSI group

Conventonal Intracytoplasmic Sperm InjectionNo intervention

Conventional ICSI; Control group

Other: Experimental

Sites

1 site in 1 country

  • Wish Fertility Hospital Pvt. LtdColombo, Sri Lanka